pmc logo image
Logo of amjpatholAmerican Journal of Pathology For AuthorsAmerican Journal of Pathology SubscribeAmerican Journal of Pathology SearchAmerican Journal of Pathology Current IssueAmerican Journal of Pathology About the JournalAmerican Journal of Pathology

Formats:

Am J Pathol. 1997 December; 151(6): 1587–1600.
PMCID: PMC1858361
Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation.
M. Riminucci, L. W. Fisher, A. Shenker, A. M. Spiegel, P. Bianco, and P. Gehron Robey
Craniofacial and Skeletal Diseases Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20892, USA.
Abstract
In addition to café-au-lait pigmentation patterns and hyperendocrinopathies, fibrous dysplasia of bone is a major finding in the McCune-Albright syndrome. Activating missense mutations of the Gs alpha gene leading to overactivity of adenylyl cyclase have been identified in patients with McCune-Albright syndrome, but the mechanism leading to the specific development of fibrous dysplasia in bone has not been elucidated. By means of specific peptide antisera and reverse transcriptase polymerase chain reaction in situ hybridization, we show that expression of Gs alpha and its mRNA is critically up-regulated during maturation of precursor osteogenic cells to normal osteoblast cells and that this pattern of expression is retained in fibrous dysplasia. A functional characterization of fibrous dysplastic tissues revealed that the fibrotic areas consist, in fact, of an excess of cells with phenotypic features of pre-osteogenic cells, whereas the lesional bone formed de novo within fibrotic areas represents the biosynthetic output of mature but abnormal osteoblasts. These cells are noted for peculiar changes in cell shape and interaction with matrix, which were mimicked in vitro by the effects of excess exogenous cAMP on human osteogenic cells. Osteoblasts involved with the de novo deposition of lesional bone in fibrous dysplasia produce a bone matrix enriched in certain anti-adhesion molecules (versican and osteonectin), and poor in the pro-adhesive molecules osteopontin and bone sialoprotein, which is in contrast to the high levels of these two proteins found in normal de novo bone. Our data indicate the need to reinterpret fibrous dysplasia of bone as a disease of cells in the osteogenic lineage, related to the effects of excess cAMP on bone cell function. They further suggest that a critical, physiological, maturation-related regulation of Gs alpha levels makes cells in the osteogenic lineage a natural target for the effects of mutations in the Gs alpha gene and may provide a clue as to why bone itself is affected in this somatic, mutation-dependent disease.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (6.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Danon M, Crawford JD. The McCune-Albright syndrome. Ergeb Inn Med Kinderheilkd. 1987;55:81–115. [PubMed]
  • Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991 Dec 12;325(24):1688–1695. [PubMed]
  • Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5152–5156. [PubMed]
  • Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, Van Wyk JJ, Merino MJ, Feuillan PP, Spiegel AM. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr. 1993 Oct;123(4):509–518. [PubMed]
  • Malchoff CD, Reardon G, MacGillivray DC, Yamase H, Rogol AD, Malchoff DM. An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the Gs alpha-subunit from a bone lesion. J Clin Endocrinol Metab. 1994 Mar;78(3):803–806. [PubMed]
  • Shenker A, Weinstein LS, Sweet DE, Spiegel AM. An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab. 1994 Sep;79(3):750–755. [PubMed]
  • Candeliere GA, Glorieux FH, Prud'homme J, St-Arnaud R. Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med. 1995 Jun 8;332(23):1546–1551. [PubMed]
  • Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest. 1996 Jul 1;98(1):30–35. [PubMed]
  • Marie PJ, de Pollak C, Chanson P, Lomri A. Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol. 1997 Mar;150(3):1059–1069. [PubMed]
  • Shenker A, Chanson P, Weinstein LS, Chi P, Spiegel AM, Lomri A, Marie PJ. Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the Gs alpha gene. Hum Mol Genet. 1995 Sep;4(9):1675–1676. [PubMed]
  • Alman BA, Greel DA, Wolfe HJ. Activating mutations of Gs protein in monostotic fibrous lesions of bone. J Orthop Res. 1996 Mar;14(2):311–315. [PubMed]
  • Bianco P, Boyde A. Alkaline phosphatase cytochemistry in confocal scanning light microscopy for imaging the bone marrow stroma. Basic Appl Histochem. 1989;33(1):17–23. [PubMed]
  • Fisher LW, Stubbs JT, 3rd, Young MF. Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta Orthop Scand Suppl. 1995 Oct;266:61–65. [PubMed]
  • Simonds WF, Goldsmith PK, Woodard CJ, Unson CG, Spiegel AM. Receptor and effector interactions of Gs. Functional studies with antibodies to the alpha s carboxyl-terminal decapeptide. FEBS Lett. 1989 Jun 5;249(2):189–194. [PubMed]
  • Bianco P, Riminucci M, Bonucci E, Termine JD, Robey PG. Bone sialoprotein (BSP) secretion and osteoblast differentiation: relationship to bromodeoxyuridine incorporation, alkaline phosphatase, and matrix deposition. J Histochem Cytochem. 1993 Feb;41(2):183–191. [PubMed]
  • Robey PG, Termine JD. Human bone cells in vitro. Calcif Tissue Int. 1985 Sep;37(5):453–460. [PubMed]
  • Owen M. The origin of bone cells. Int Rev Cytol. 1970;28:213–238. [PubMed]
  • Greco MA, Steiner GC. Ultrastructure of fibrous dysplasia of bone: a study of its fibrous, osseous, and cartilaginous components. Ultrastruct Pathol. 1986;10(1):55–66. [PubMed]
  • Miller SS, Wolf AM, Arnaud CD. Bone cells in culture: morphologic transformation by hormones. Science. 1976 Jun 25;192(4246):1340–1343. [PubMed]
  • Fedarko NS, Termine JD, Young MF, Robey PG. Temporal regulation of hyaluronan and proteoglycan metabolism by human bone cells in vitro. J Biol Chem. 1990 Jul 25;265(21):12200–12209. [PubMed]
  • Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J Histochem Cytochem. 1990 Nov;38(11):1549–1563. [PubMed]
  • Bianco P, Silvestrini G, Termine JD, Bonucci E. Immunohistochemical localization of osteonectin in developing human and calf bone using monoclonal antibodies. Calcif Tissue Int. 1988 Sep;43(3):155–161. [PubMed]
  • Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. Expression of bone sialoprotein (BSP) in developing human tissues. Calcif Tissue Int. 1991 Dec;49(6):421–426. [PubMed]
  • Mark MP, Butler WT, Prince CW, Finkelman RD, Ruch JV. Developmental expression of 44-kDa bone phosphoprotein (osteopontin) and bone gamma-carboxyglutamic acid (Gla)-containing protein (osteocalcin) in calcifying tissues of rat. Differentiation. 1988;37(2):123–136. [PubMed]
  • Mintz KP, Grzesik WJ, Midura RJ, Robey PG, Termine JD, Fisher LW. Purification and fragmentation of nondenatured bone sialoprotein: evidence for a cryptic, RGD-resistant cell attachment domain. J Bone Miner Res. 1993 Aug;8(8):985–995. [PubMed]
  • Denhardt DT, Lopez CA, Rollo EE, Hwang SM, An XR, Walther SE. Osteopontin-induced modifications of cellular functions. Ann N Y Acad Sci. 1995 Apr 21;760:127–142. [PubMed]
  • Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption--a hypothesis. Calcif Tissue Int. 1981;33(4):349–351. [PubMed]
  • Bianco P, Bonucci E. Endosteal surfaces in hyperparathyroidism: an enzyme cytochemical study on low-temperature-processed, glycol-methacrylate-embedded bone biopsies. Virchows Arch A Pathol Anat Histopathol. 1991;419(5):425–431. [PubMed]
  • Young MF, Findlay DM, Dominguez P, Burbelo PD, McQuillan C, Kopp JB, Robey PG, Termine JD. Osteonectin promoter. DNA sequence analysis and S1 endonuclease site potentially associated with transcriptional control in bone cells. J Biol Chem. 1989 Jan 5;264(1):450–456. [PubMed]
  • Kerr JM, Fisher LW, Termine JD, Wang MG, McBride OW, Young MF. The human bone sialoprotein gene (IBSP): genomic localization and characterization. Genomics. 1993 Aug;17(2):408–415. [PubMed]
  • Everitt EA, Sage EH. Expression of SPARC is correlated with altered morphologies in transfected F9 embryonal carcinoma cells. Exp Cell Res. 1992 Mar;199(1):134–146. [PubMed]
  • Noda M, Rodan GA. Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J Cell Biol. 1989 Feb;108(2):713–718. [PubMed]